Pharmaceutical feasibility

Specialty plants. These plants are capable of producing small amounts of a variety of products. Such plants are common in fine chemicals, pharmaceutic s, foods, and so on. In specialty plants, the margins are usually high, so factors such as energy costs are important but not life-and-death issues. As the production amounts are relatively small, it is not economically feasible to dedicate processing equipment to the manufac ture of only one product. Instead, batch processing is utilized so that several products (perhaps hundreds) can be manufactured with the same process equipment. The key issue in such plants is to manufacture consistently each product in accordance with its specifications. 

GL 24] [R 1] [P 26] The feasibility of safely carrying out the oxidation of cyclopentadiene by singlet oxygen to 2-cyclopentene-l, 4-diol was demonstrated [40]. The explosive intermediate endoperoxide was generated and without isolation used onsite for a subsequent hydration reaction. By reduction with thiourea the pharmaceutically important product 2-cyclopentene-l,4-diol was so obtained. 

Pharmaceutical scientists have developed improved suspension dosage forms to overcome problems of poor physical stability and patient-perceived discomfort attributed to some active ingredients. An important development aspect of any suspension is the ability to resuspend easily any settled particles prior to instillation in the eye and ensure that a uniform dose is delivered. It would be ideal to formulate a suspension that does not settle since the patient may not always follow the labeled instructions to shake well before using. However, this is usually not feasible or desirable since the viscosity required to retard settling of the insoluble particles completely would likely be excessive for a liquid eyedrop. The opposite extreme, of allowing complete settling between doses, usually leads to a dense layer of agglomerated particles that are difficult to resuspend. 

M. Mumenthaler, C. C. Hsu, and R. Pearlman, Feasibility study on spray-drying protein pharmaceuticals recombinant human growth hormone and tissue-type plasminogen activator, Pharm. Res, 11(1), 12 (1994). 

Besides their essential roles in nature, isoprenoids are of commercial importance in industry. Some isoprenoids have been used as flavors, fragrances, spices, and food additives, while many are used as pharmaceuticals to treat an array of human diseases, such as cancer (Taxol), malaria (artemisinin), and HIV (coumarins). In contrast to the huge market demand, isoprenoids are present only in low abundance in their host organisms. Thus, isolation of the required isoprenoids consumes a large quantity of natural resources. Furthermore, owing to their structural complexity, total chemical synthesis is often not commercially feasible. For these reasons, metabolic engineering may provide an alternative to produce these valuable isoprenoids [88,89]. 

When sufficiently high levels of expression and protein accumulation are achieved, efficient downstream processing protocols must be developed to insure product quality and the economic feasibility of production. As the demand for safe, recombinant pharmaceutical proteins continues to expand, the market potential of plant-produced recombinant proteins is considerable. Molecular farming can produce recombinant proteins at a lower cost than traditional expression systems based on microbial or animal cell culture, and without the risk of contamination with human pathogens. 

At the health care provider level, choices will be made among many therapeutic regimens that differ in effectiveness and cost. At the producer level, pharmaceutical companies must decide whether targeted drug development is economically feasible. Will there be a sufficient return on investment to justify the risks involved in pharmacogenomic research Will companies only pursue research and drug development for diseases for which there is... 

Although most work to date has focused on the enzyme inhibition aspect, it is possible that the monoclonal VAP-1 antibody discussed above may well be closer to the clinic. The task of designing small molecules to interfere with cell-cell recognition is certainly feasible, but this will not be a trivial effort, more akin to the search for selective selectin antagonists which has proven to be very challenging. As confidence grows in the pharmaceutical industry that SSAO/VAP-1 is a validated target, it is inevitable that considerable resources will be directed to all avenues to block the functional action of this protein. 

In addition to rodent studies, regulatory guidelines for pharmaceuticals require that repeated dose safety studies of up to nine months (in the United States, six months elsewhere) in duration be conducted in a nonrodent species. The most commonly used nonrodent species is the dog, followed by the monkey and pig. Another nonrodent model used to a limited extent in systemic safety evaluation is the ferret. The major objectives of this chapter are (1) to discuss differences in rodent and nonrodent experimental design, (2) to examine the feasibility of using the dog, monkey, pig, and ferret in safety assessment testing, and (3) to identify the advantages and limitations associated with each species. 

---